Crossref
Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?
Oncology in Clinical Practice · 15.01.2026 · 22
DOI: 10.5603/ocp.109345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 15.01.2026. Verfasst von Piotr J. Wysocki.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wysocki, P. J. (2026). Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?. Oncology in Clinical Practice, 22(0). https://doi.org/10.5603/ocp.109345
Vancouver
Wysocki PJ. Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?. Oncology in Clinical Practice. 2026;22(0). doi:10.5603/ocp.109345
BibTeX
@article{Wysocki2026,
author = {Wysocki, Piotr J.},
title = {Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?},
journal = {Oncology in Clinical Practice},
year = {2026},
volume = {22},
number = {0},
doi = {10.5603/ocp.109345}
}
EUVIMED